

Appendix 4E

1. Company details

Name of entity: Oakridge International Limited
 ABN: 89 122 203 196
 Reporting period: For the year ended 30 June 2026
 Previous period: For the year ended 30 June 2025

2. Results for announcement to the market

Revenues from ordinary activities	Up	42%	\$ 3,446,008
Profit from continuing activities after tax attributable to the owners of Oakridge International Limited	Up	185%	109,171
Profit for the year attributable to the owners of Oakridge International Limited	Up	185%	109,171

Dividends

No dividend has been declared or paid for the year ended 30 June 2026 (30 June 2025: \$nil).

Brief explanation of any of the figures reported above

Revenue from this current year has increased by \$1,012,668 or about 42% as compared to the prior year and this increase is mainly attributable to an increase in sales as a result of increased business development activities. Profit attributable to shareholders improved from a loss of \$128,795 in the prior year to a profit of \$109,171 in the current year.

3. Net tangible assets

	Reporting Period Cents	Previous Period Cents
Net tangible assets / (liabilities) per ordinary security	4.08	2.76

Right-of-use assets recognized under AASB 16 Leases are classified as intangible assets for the purpose of determining the net tangible assets

4. Control gained over entities

Name of entities (or group of entities) Date control gained
 None. N/A-

5. Loss of control over entities

<i>Name of entities (or group of entities)</i>	<i>Date control lost</i>
None	N/A-

6. Details of associates and joint venture entities

There are no associates or joint ventures during the period or previous reporting period.

7. Audit qualification or review

The financial statements have been audited.

Details of audit/review dispute or qualification (if any):

Not applicable.

8. Attachments

Details of attachments (if any):

The audited consolidated annual report of Oakridge International Limited for the year ended 30 June 2025 is attached.

Signature:



Con Unerkov
Chairman

24 August 2026

Oakridge International Limited

ABN 89 122 203 196

Oakridge International Limited

**Annual Financial Report
for the financial year ended
30 June 2026**

Table of contents

	Page
Corporate directory	1
Directors' report	2
Auditor's independence declaration	14
Corporate governance statement	15
Annual financial report	16
Consolidated entity disclosure statement	44
Directors' declaration	45
Independent auditor's report to the members	47

Corporate directory

Directors	Mr. Con Unerkov (Executive chairman and director) Mr. Peter Whelan (Non-executive director) Mr. Wally Pastuch (Non-executive director)
Company secretary	Ms. Julie Edwards
Registered office in Australia	Suite 3 Level 3, 89 Pirie Street Adelaide SA, 5000
Principal office in Australia	Suite 3 Level 3, 89 Pirie Street Adelaide SA, 5000 Phone: +61 8 8223 0200
Share registry	MUFG Corporate Markets Limited Tower 4, 727 Collins Street Melbourne VIC 3008
Auditor	Moore Australia Audit (Vic) Level 44 600 Bourke Street Melbourne, Victoria, 3000
Stock exchange listing	Australian Securities Exchange Ltd OAK - listed ordinary shares
Website address	www.oakridgeint.com

Directors' Report

Your directors present their report on the consolidated entity (referred to hereafter as the "Group" or "Oakridge International" or "the Company") consisting of Oakridge International Limited and its controlled entities for the financial year ended 30 June 2026.

Directors

The following persons were directors of Oakridge International Limited during the financial year and up to the date of this report unless otherwise stated:

Mr. Con Unerkov	Executive Chairman, CEO and director
Mr. Peter Whelan	Non-executive director
Mr. Wally Pastuch	Non-executive director

Company secretaries

Ms. Julie Edwards

Principal activities and changes in state of affairs

Oakridge International is engaged in the business of selling professional healthcare technology equipment and solutions to healthcare facilities. Oakridge International develops and distributes its own range of nurse call hardware and software solutions for use across multiple healthcare sectors including hospitals, aged care, disability care and supported independent living.

Oakridge International continues to focus on expanding into delivering assisted independent living technologies utilising synergies with Oakridge International's Internet of Things (IoT) platform.

During the year, the Company progressed strategic planning around enterprise grade reporting and AI-enabled capabilities for its NuCaMS platform and evaluated an opportunity to extend its platform into a broader connected clinical care offering, combining workflow data with complementary consumables and non invasive monitoring inputs to support a more proactive model of care.

The Company continues to look for opportunities to expand its business and revenue base by exploring other emerging business in the technology sector focusing on IoT and Healthcare.

There were no significant changes in the nature of the Company's activities during the year, nor were there any significant changes in the state of the Company's affairs.

Dividends

No amounts have been paid or declared by way of dividend during the year.

Significant events after the balance date

The significant events after the balance sheet date are set out in Note 28 of the financial statements.

Review and results of operations

The Company realised a profit after tax for the full-year of \$109,171 (2025: loss of \$128,795) from its continuing operations and continued to deliver strong operational performance through its commitment to technology, innovation, quality service and strategic expansion.

The following provides a summary of the Company's activities during the course of the financial year.

Product Development Program

The Company placed a strong emphasis on advancing its suite of healthcare technology products. The product roadmap continued to align with the evolving AS8311:2024 Nurse Call Standard, supporting compliance and competitive positioning. Key achievements included:

- Further enhancements to the NuCaMS and NuCaMS Enterprise platforms, including improved reporting, scalability, integration and performance;
- Completion of RTLS call point and resident pendant work;
- Completion and market demonstration of first-stage enterprise reporting, with further reporting and integration features continuing toward broader deployment milestones;
- Refined its LED and LCD annunciator display modules;
- Progressed software development across administration, authentication, reporting and single sign-on, including validated cloud-based integration with Microsoft Azure; and
- A continued mobile application development.

Directors' Report (continued)

Sales, Channel Growth & Project Delivery

The Company delivered a significant volume of project work across multiple regions and care sites throughout the year, reflecting robust growth both from direct sales and through its expanding partner channel. A substantial body of contracted work was invoiced and converted through delivery milestones and a material active quote book was maintained across a range of sectors and geographies.

Installations and staged delivery progressed across multiple customer sites, with jobs moving through programming, first-fix, component delivery, commissioning and installation phases.

Assisted living and accommodation-related programs also continued to expand, including further integrated and assistive technology deployments in supported living environments.

Business Development and Market Engagement

The Company actively built new and reinforced existing relationships with key partners across aged care, disability care, hospital and retirement living settings, including engagements involving nurse call upgrades, wireless systems, RTLS deployments and multisite programs.

Installation activity was supported by delivered stock, replacement server arrangements, customer presentations and ongoing technical support, with additional opportunities advanced through product demonstrations and technical submissions to direct and channel prospects.

The project pipeline continues to include both partner and direct opportunities across Australian healthcare and international markets, with management expecting current channel activity and project conversion to support revenue into FY2027.

Operational Effectiveness & Expense Management

The Company continued to refine its operational processes and expense controls. Adoption of Zoho Books and associated inventory platforms progressed, improving internal communications, data consistency and alignment between operations and financial control.

Human Resources

Project rostering and resource allocation continued to be managed around delivery requirements, supporting consistent service delivery and project execution across the business.

Marketing & Digital Strategy

The Company strengthened its digital presence throughout the year, integrating website and social media channels with partner-related promotional work and conference participation, including its participation, alongside one of its Queensland partners, in the ITAC Conference in Brisbane in May 2026.

RTLS content and specification materials were progressed for market engagement, while website refresh and lead-generation enhancement activities remained ongoing, contributing to improved visibility, lead generation and sales conversion.

Foundation for Continuous Improvement

The business continued readiness activities in relation to ISO 9001:2015 and ISO 27001 related certification.

The Company leveraged the operational improvements and system upgrades instituted during the year as the foundation for further progress in the year ahead. These measures, together with discipline in expense and working capital management, are an integral part of the Company's daily operations, ensuring ongoing enhancements to operational efficiency and performance.

Prospects

Australia's ageing population, combined with a persistent shortfall in the aged-care workforce and continued growth in government aged care funding, is expected to support long-term demand for care technology, workflow efficiency and compliance solutions of the kind the Group provides.

The Company will continuously monitor its overhead costs and cashflow, continue to look at strengthening its capital base and seek strategic partners to further develop its business. The Company has strengthened its position in the healthcare technology sector, underpinned by a proven track record of project delivery, an integrated product suite spanning nurse call and assistive technologies and enterprise infrastructure supporting scalable deployments.

The Company will continue to assess complementary product and technology opportunities that may enhance its healthcare solution offering and extend its platform capabilities, including potential AI-related applications and adjacent areas of the care technology sector, although any such opportunities remain at an early stage and subject to ongoing evaluation, development, commercial assessment and any board and/or regulatory approval that may be required.

Information on directors

The names and details of Oakridge International Limited's directors as at balance date and up to the date of this report are set out below, unless noted otherwise.

Mr. Con Unerkov (Executive chairman, CEO and director)

Experience and expertise

Mr. Con Unerkov ("Mr. Unerkov"), was originally appointed non-executive chairman and director on 31 December 2019. On the 3 February 2021, Mr. Unerkov was appointed into an executive role as CEO and remained as Chairman and Director.

Mr. Unerkov is an Australian based businessman with more than 25 years of local and international senior executive experience. Throughout his career, Mr. Unerkov has worked as an executive and chief executive officer for a number of companies both in the private and public sectors. He has significant experience in the financial markets with a focus on structuring, M&A and corporate financing for both private and public companies, simultaneously providing parallel guidance for companies to gain market recognition, shareholder value and liquidity.

Mr. Unerkov is also the Chairman and CEO of Integrated Media Technology Limited, a company listed on the Nasdaq Capital Markets (NASDAQ: "IMTE")

Other current ASX directorships

Nil

Former ASX directorships in last 3 years

Nil

Special responsibilities

Executive Chairman of the Board of Directors

Chief Executive Officer

Member of the Nomination and Remuneration Committee

Interests in shares and options

16,898,439 fully paid ordinary shares in the Company through an entity associated with Mr. Unerkov.

599,970 unlisted options in the Company through an entity associated with Mr. Unerkov, exercisable at 10 cents per option, expiring 19 December 2026.

Mr. Peter Whelan (Non-executive director)

Experience and expertise

Mr. Peter Whelan ("Mr. Whelan"), was appointed non-executive director on 29 January 2021. Mr Whelan is a Chartered Accountant with over 50 years' experience as a professional accountant. He has held positions as Managing Partner and Chairman of Partners of a major mid-tier accounting firm in South Australia. He practiced mainly in the areas of corporate advisory and audit.

Mr Whelan has extensive experience as an auditor and adviser in the aged care and retirement living sectors. He has also prepared experts reports for capital raisings and company listings.

Mr Whelan is currently a member of the Board and Finance Committee of a major South Australian charity that provides affordable accommodation to those in need, a member of the Adelaide Motorsport Festival Advisory Committee and a director of a family business operating in the retail clothing and foot-wear sector.

Other current ASX directorships

Nil

Former ASX directorships in last 3 years

Nil

Special responsibilities

Member of the Audit Committee (Chair)

Member of the Nomination and Remuneration Committee

Interests in shares and options

Nil

Mr. Wally Pastuch (Non-executive director)

Experience and expertise

Mr. Wally Pastuch ("Mr. Pastuch"), was appointed non-executive director on 03 March 2025. Mr Pastuch is an accomplished professional with over 40 years of experience across the automotive, insurance and IT industries

His career includes implementing computerised inventory management systems at Ford Australia, serving as Regional Manager for Victoria and Tasmania at Mitsubishi Motors Australia Ltd and developing specialised insurance products with Eric Insurance, an affiliate of Insurance Australia Group.

Throughout his career, Mr Pastuch has demonstrated remarkable adaptability, technological insight, and a consistent ability to drive business performance and innovation across multiple sectors.

Other current ASX directorships

Nil

Former ASX directorships in last 3 years

Nil

Special responsibilities

Member of the Audit Committee

Member of the Nomination and Remuneration Committee (Chair)

Interests in shares and options

Nil

Company secretaries

Ms. Julie Edwards

Ms. Julie Edwards ("Ms. Edwards") has had significant experience and involvement in the management of accounting and finance functions of companies. Ms. Edwards holds a Bachelor of Commerce, is a member of CPA Australia, holds a CPA Public Practice Certificate and is a registered Tax Agent.

Meetings of directors

The number of meetings of the Group's Board of Directors (including meetings of the Board committees) held during the year, and the numbers of meetings attended by each director are as follows:

	Board of Directors		Audit Committee	
	Eligible	Attended	Eligible	Attended
Mr. Con Unerkov	4	4	-	-
Mr. Peter Whelan	4	4	2	2
Mr. Wally Pastuch	4	4	2	2

There were no remuneration committee meetings during the financial year.

The above does not include any circular resolutions approved by the board and independent board committee meetings during the year from 1 July 2025 to 30 June 2026.

Shares under option

At the end of the financial year and at the date of this report, the outstanding options over ordinary shares in the Group are:

On 14 November 2023, the Company issued 306,480 unlisted options to its employees which are exercisable at \$0.10 per option and expire on 13 November 2026. As at the balance date and the date of this report, none of the 306,480 unlisted options have been exercised.

On 20 December 2023, the Company issued 599,970 unlisted options exercisable at \$0.10 expiring 19 December 2026 to an entity associated with Con Unerkov, a director of the Company. As at the balance date and the date of this report, none of the 599,970 unlisted options have been exercised.

On 20 June 2024 at a members meeting, the shareholders approved the issuance of 7,142,857 unlisted options with an exercise price of \$0.07 and an expiry date of 30 June 2026 to Montague Capital Pty Ltd, an entity associated with Mr. Unerkov, a director of the Company. On 30 June 2026, 4,999,943 options were exercised by Montague Capital Pty Ltd and the remaining amount of 2,142,914 options expired without exercise or conversion.

The holders of these options do not have any rights to participate in any share issue of the company or receive dividends before the options are exercised.

Remuneration report (audited)

(a) Policy for determining the nature and amount of key management personnel remuneration

The Board of Directors of Oakridge International is responsible for determining and reviewing compensation arrangements for the directors and the executive team. The Board's remuneration policy is to ensure that the remuneration package properly reflects the person's duties and responsibilities, with the overall objective of ensuring maximum stakeholder benefit from the retention of a high-quality board and executive team. Such officers are given the opportunity to receive their base emolument in a variety of forms, with the intention that the manner of payment chosen by the recipient is optimal to the recipient without creating an undue cost on the Group.

In accordance with best practice corporate governance, the structure of non-executive director and executive remuneration is separate and distinct.

The Board remains confident that its remuneration policy and the level and structure of its executive remuneration is suitable for the Group and its shareholders.

(i) Non-executive director remuneration

Objective

The Board seeks to set aggregate remuneration at a level which provides the Group with the ability to attract and retain directors of the highest calibre, whilst incurring a cost which is acceptable to shareholders.

Structure

Remuneration of non-executive directors is determined by the Board, within the maximum amount approved by the shareholders from time to time (currently set at an aggregate of \$300,000 per annum). The Board intends to undertake an annual review of its performance and the performance of the Board committees against goals set at the start of the year.

The amount of aggregate remuneration sought to be approved by shareholders and the manner in which it is apportioned amongst directors is reviewed annually. The Board considers advice from time to time from external consultants as well as the fees paid to non-executive directors of comparable companies when undertaking the annual review process. During the financial year, the Board did not receive any advice from external consultants in respect to the annual review process.

Certain directors received a fee for being a director of the Group, which was not linked to that director's performance. Directors who are called upon to perform extra services beyond the director's ordinary duties may be paid additional fees for those services.

The remuneration of non-executive directors for the year ended 30 June 2026 is detailed in this remuneration report.

(ii) Senior executive remuneration

Objective

The Group aims to reward executives with a level and mix of remuneration commensurate with their position and responsibilities within the Group so as to:

- Reward executives for Group and individual performance against targets set by reference to appropriate benchmarks;
- Align the interest of executives with those of shareholders;
- Link reward with the strategic goals and performance of the Group; and
- Ensure total remuneration is competitive by market standards.

Structure

In determining the level and make-up of executive remuneration, the Board has had regard to market levels of remuneration for comparable executive roles. It is the Board's policy that employment contracts are entered into with all senior executives.

Remuneration report (continued)

(iii) Variable remuneration – short and long term incentives

Objective

The objectives of the incentive arrangements are to:

- Recognise the ability and efforts of the employees of the Group who have contributed to the success of the Group and to provide them with rewards where deemed appropriate;
- Provide an incentive to the employees to achieve the long-term objectives of the Group and improve the performance of the Group; and
- Attract persons of experience and ability to employment with the Group and foster and promote loyalty between the Group and its employees.

Structure

No short or long-term incentives have been provided to executive management during the reporting period.

(b) Remuneration, Group performance and shareholder wealth

The development of remuneration policies and structure are considered in relation to the effect on Group performance and shareholder wealth. They are designed by the Board to align Director and Executive behaviour with improving Group performance and ultimately shareholder wealth.

The performance of the consolidated entity for five years to 30 June 2026 are summarised below:

	2026	2025	2024	2023	2022
Profit/(loss) attributable to owners of the Group (dollars)	109,171	(128,795)	(761,248)	(116,112)	(531,030)

The factors that are considered to affect total shareholders return ("TSR") are summarised below:

	2026	2025	2024	2023	2022
Share price (dollars)	0.072	0.060	0.071	0.072	0.073
Change in share price	0.012	(0.011)	0.001	0.001	-
Dividends declared	Nil	Nil	Nil	Nil	Nil
Basic and diluted EPS (cents)	0.40	(0.48)	(0.03)	(0.01)	(0.03)

(c) Key management personnel

KMP are the non-executive directors, executive directors, and employees who have the authority and responsibility for planning, directing and controlling the activities of the consolidated entity. On that basis, the individuals classified as KMP are set out below:

Name	Title
Mr. Con Unerkov	Executive chairman, CEO and director
Mr. Peter Whelan	Non-executive director
Mr. Wally Pastuch	Non-executive director

Remuneration report (continued)

(d) Details of remuneration

Compensation paid, payable or provided by the Group or on behalf of the Group, to key management personnel is set out below. Key management personnel include all directors of the Group and certain executives who, in the opinion of the Board and Chairman, have authority and responsibility for planning, directing and controlling the activities of the Group directly or indirectly.

No employees of the Company, other than the Executive Chairman, are considered by the Board to have executive responsibility.

e) Details of remuneration

2026	Short-term employee benefits	Post-employment benefits	Termination benefits	Share-based payments		Long-term employee benefits	Total	Proportion of remuneration that is performance based %
Name	Cash salary and fees \$	Super-annuation \$	Cash \$	Shares \$	Options \$	\$	Total \$	
<i>Non-executive directors</i>								
Mr. Wally Pastuch	24,000	-	-	-	-	-	24,000	-
Mr. Peter Whelan	24,000	-	-	-	-	-	24,000	-
Total non-executive directors	48,000	-	-	-	-	-	48,000	-
<i>Executive directors</i>								
Mr. Con Unerkov ⁽¹⁾	199,992	-	-	-	-	-	199,992	-
Total executive directors	199,992	-	-	-	-	-	199,992	-
Total KMP compensation	247,992	-	-	-	-	-	247,992	-

(1) Mr. Con Unerkov's remuneration is paid via a consultancy agreement to a company controlled by Mr. Unerkov.

2025	Short-term employee benefits	Post-employment benefits	Termination benefits	Share-based payments		Long-term employee benefits	Total	Proportion of remuneration that is performance based %
Name	Cash salary and fees \$	Super-annuation \$	Cash \$	Shares \$	Options \$	\$	Total \$	
<i>Non-executive directors</i>								
Mr. Elvis Diao	16,000	-	-	-	-	-	16,000	-
Mr. Peter Whelan	24,000	-	-	-	-	-	24,000	-
Mr. Wally Pastuch	8,000	-	-	-	-	-	8,000	-
Total non-executive directors	48,000	-	-	-	-	-	48,000	-
<i>Executive directors</i>								
Mr. Con Unerkov ⁽¹⁾	199,992	-	-	-	-	-	199,992	-
Total executive directors	199,992	-	-	-	-	-	199,992	-
Total KMP compensation	247,992	-	-	-	-	-	247,992	-

(1) Mr. Con Unerkov's remuneration is paid via a consultancy agreement to a company controlled by Mr. Unerkov.

Remuneration report (continued)

(f) Service & consultancy agreements

On appointment to the Board, non-executive directors enter into a service agreement with Oakridge International Limited in the form of a letter of appointment ("Director Agreement"). The letter summarises the Board policies and terms, including compensation, relevant to the office of director. Remuneration and other terms of employment for the CEO and the other key management personnel are also formalised in service agreements.

Mr. Con Unerkov (Executive Chairman and Chief Executive Officer)

Mr. Con Unerkov was originally appointed Chairman and Non-Executive Director on 31 December 2019. On 3 February 2021, Mr. Unerkov was appointed into an executive role as Chief Executive Officer and remained as Chairman and Director. Mr. Unerkov is contracted at a monthly remuneration of \$16,666 via a consultancy agreement with a company controlled by Mr Unerkov. The consultancy agreement has no fixed term and is terminatable by either party with six months' notice.

Mr. Peter Whelan (Non-executive director)

Mr. Whelan was appointed Non-Executive Director on 29 January 2021. Mr. Whelan was originally entitled to remuneration under his Director Agreement of \$1,500 per month which was changed to \$2,000 per month from 1 October 2023.

Mr. Wally Pastuch (Non-executive director)

Mr. Pastuch was appointed Non-Executive Director on 03 March 2025. Mr. Pastuch is entitled to remuneration under his Director Agreement of \$2,000 per month.

(g) Share-based compensation

Options may be granted to attract and retain key management personnel. The Board has rules that contain restrictions on removing the 'at risk' aspect of the options granted to executives. Executives may not enter into any transactions designed to remove the 'at risk' aspect of an instrument before it vests.

There are no performance hurdles attached to options granted. In the event of termination (specified circumstances) only vested options are entitled to be exercised. Unvested options are forfeited.

The assessed fair value at grant date of options granted to the individuals is allocated equally over the period from grant date to vesting date, and the amount is included in the remuneration tables above. Fair values at grant date are independently determined using a Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk-free interest rate for the term of the option.

No options were granted to directors or any other key personnel during the financial year. In prior years, the following options were granted to directors, other key personnel and staff:

On 14 November 2023, the Company issued 306,480 unlisted options to its employees (none of which are considered by the Board to be Executive) which are exercisable at \$0.10 per option and expire on 13 November 2026. As at the balance date and the date of this report, none of the 306,480 unlisted options have been exercised.

On 20 December 2023, the Company issued 599,970 unlisted options exercisable at \$0.10 expiring 19 December 2026 to an entity associated with Mr. Unerkov, a director of the Company. As at the balance date and the date of this report, none of the 599,970 unlisted options have been exercised.

(h) Equity instruments disclosures relating to key management personnel

(i) Unlisted option holdings

No unlisted options over ordinary shares in the Group were issued during the year.

On 20 December 2023, the Company issued 599,970 unlisted options exercisable at \$0.10 expiring 19 December 2026 to an entity associated with Mr. Unerkov, a director of the Company. As at the balance date and the date of this report, none of the 599,970 unlisted options have been exercised.

Remuneration report (continued)

(ii) Ordinary share holdings

Ordinary shares held directly, indirectly or beneficially by each key management person, including their personally related entities, are shown below.

2026	Balance at start of the year	Acquired during the year	Other changes¹	Balance at the end of the year
Mr. Con Unerkov ²	11,898,496	4,999,943	-	16,898,439
Mr. Peter Whelan	-	-	-	-
Mr. Wally Pastuch	-	-	-	-

2025	Balance at start of the year	Acquired during the year	Other changes¹	Balance at the end of the year
Mr. Con Unerkov ²	11,898,496	-	-	11,898,496
Mr. Peter Whelan	-	-	-	-
Mr. Wally Pastuch	-	-	-	-

1. the amount in other changes is the individual's shareholding at the date he commenced or ceased to be a key management person, as applicable, in addition to the individual's on-market trading.

2. Held through Montague Capital Pty Ltd, an entity associated with Con Unerkov, a Director of the Company.

(iii) Listed option holdings

No listed options over ordinary shares in the Group were held during the year by directors of the Group and other key management personnel of the Group, including their personally related parties.

(i) Loans to key management personnel

There were no loans to key management personnel at any time during the financial year.

(j) Other transactions with key management personnel

Other than as disclosed in Note 21, there were no other transactions with key management personnel at any time during the financial year.

(k) External remuneration consultant advice

No external remuneration consultant has been utilised during the financial year.

END OF REMUNERATION REPORT

Insurance of officers and indemnities

During or since the end of the year, the Group has not given any indemnity to a current or former officer or auditor against a liability or made any agreement under which an officer or auditor may be given any indemnity of the kind covered by the *Corporations Act 2001*.

During the year, the Group paid premiums in respect of directors' and officers' indemnity insurance contracts for the period ended 30 June 2026. The insurance contracts offer continuing indemnity to officers of the Group where the person is no longer an officer at the time the claim is made. The Group paid premiums of \$26,085 (2025: \$35,670) to insure the directors of the Group during the financial year. This does not include such liabilities that arise from conduct involving a wilful breach of duty by the officers or the improper use by the officers of their position or of information to gain advantage for them or someone else or to cause detriment to the Group. It is not possible to apportion the premium between amounts relating to the insurance against legal costs and those relating to other liabilities.

Proceedings on behalf of the Group

The Group is not aware that any person has applied to the court under section 237 of the *Corporations Act 2001* for leave to bring proceedings on behalf of the Group, or to intervene in any proceedings in which the Group is a party, for the purpose of taking responsibility on behalf of the Group for all or part of those proceedings. No proceedings have been brought or intervened in on behalf of the Group with leave of the court under section 237 of the *Corporations Act 2001*.

Environmental regulation and performance

The Group is not subject to any particular or significant environmental regulations.

Non-audit services

Moore Australia continues in office in accordance with section 327 of the *Corporations Act 2001*. The Group may decide to employ the auditor on assignments additional to their statutory audit duties where the auditor's expertise and experience with the Group are important. Fees the Group paid or owed to the auditors for these services during the year are included in the following table:

	2026 \$	2025 \$
<u>Audit and other assurance services:</u>		
Audit and review of financial report	54,000	47,567
<u>Non-audit services:</u>		
Tax and other services	-	-
Total remuneration	54,000	47,567

The Board of directors has considered the position and, in accordance with advice received from the Audit Committee, is satisfied that the provision of the non-audit services is compatible with the general standard of independence for auditors imposed by the *Corporations Act 2001*.

Rounding of amounts

The Group is of a kind referred to in ASIC Corporations (Rounding in Financial/Directors' Report) Instrument 2016/191, relating to the "rounding" of amounts in the directors' report and financial report. The Group has rounded amounts in the directors' report and financial report to the nearest dollar, in accordance with that instrument.

Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the *Corporations Act 2001* is attached to this report.

This report is made in accordance with a resolution of directors.



Con Unerkov
Executive Chairman and CEO
Date: 24 August 2026

Moore Australia**VICTORIA**

Level 44, 600 Bourke Street
Melbourne VIC 3000
T +61 3 9608 0100

Level 3, 237 Ryrie Street
Geelong VIC 3220
T +61 3 5215 6800

TASMANIA


Level 3, 63-65 Cameron Street
Launceston TAS 7250
T +61 3 6334 0500

victoria@moore-australia.com.au
www.moore-australia.com.au

**AUDITOR'S INDEPENDENCE DECLARATION
UNDER S 307C OF THE CORPORATIONS ACT 2001
TO THE DIRECTORS OF OAKRIDGE INTERNATIONAL LIMITED AND CONTROLLED ENTITIES**

As lead engagement partner for the audit of Oakridge International Limited and controlled entities for the year ended 30 June 2026, I declare that, to the best of my knowledge and belief, there have been:

- i. no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the audit; and
- ii. no contraventions of any applicable code of professional conduct in relation to the audit.



ANDREW JOHNSON
Partner – Audit and Assurance
[Moore Australia Audit \(VIC\)](#)
Melbourne, Victoria
24 August 2026



Moore Australia Audit (VIC)
ABN 16 847 721 257
Chartered Accountants

Corporate governance statement

Oakridge International Limited has published its corporate governance statement on its website. It can be found at <https://www.oakridgeint.com/wp-content/uploads/2026/08/Oakridge-Corporate-Governance-Statement-2026.pdf>

Annual financial report

	Page
Financial statements	
Consolidated statement of profit or loss and other comprehensive income	17
Consolidated statement of financial position	18
Consolidated statement of changes in equity	19
Consolidated statement of cash flows	20
Notes to the financial statements	21
Consolidated entity disclosure statement	44
Directors' declaration	45
Independent auditor's report to the members	47

These financial statements cover the Group consisting of Oakridge International Limited and its subsidiaries. The financial report is presented in Australian currency.

Oakridge International Limited is a listed public company limited by shares, incorporated and domiciled in Australia and listed on the Australian Securities Exchange.

The principal place of business is:
Suite 3 Level 3, 89 Pirie Street
Adelaide SA 5000

The registered office is:
Suite 3 Level 3, 89 Pirie Street
Adelaide SA 5000

A description of the nature of the Group's operations and its principal activities is included in the review of operations and activities on page 2.

The financial statements were authorised for issue by the directors on 24 August 2026. The Group has the power to amend and reissue the financial statements.

Through the use of the internet, we have ensured that our corporate reporting is timely, complete, and available globally at minimum cost to the Group. All press releases, financial reports and other information are available on our website: www.oakridgeint.com.

Oakridge International Limited
Consolidated Statement of Profit or Loss and Other Comprehensive Income
For the year ended 30 June 2026

	Note	2026 \$	2025 \$
Revenue and other income	5	3,446,008	2,433,340
Cost of sales: inventories and other cost of sales		(1,401,242)	(1,112,101)
Employee and contracting expenses		(939,522)	(724,267)
Finance costs		(4,441)	(7,774)
Directors' remuneration		(247,992)	(247,992)
Consulting and advisory fees		(60,000)	(180,000)
Occupancy costs		(47,595)	(46,117)
Travel		(30,057)	(33,225)
Marketing and promotion costs		(38,228)	(48,181)
Professional and legal fees		(137,160)	(127,524)
Recovery of bad debts expenses		-	-
Depreciation expense	13	(22,626)	(13,706)
Foreign currency losses		(14,110)	(2,386)
Other expenses		(292,973)	(246,803)
Reversal of impairment loss on inventory		-	250,000
ROU amortisation expense	17	(100,891)	(100,891)
Profit/(loss) before income tax		109,171	(207,627)
Income tax benefit	7	-	78,832
Profit/(loss) from continuing operations		109,171	(128,795)
Loss from discontinued operations, net of income tax		-	-
Total profit/(loss) for the financial year		109,171	(128,795)
Other comprehensive income		-	-
Total comprehensive income		109,171	(128,795)
Total profit/(loss) and comprehensive income for the financial year attributable to:			
Owners of the parent		109,171	(128,795)
Non-controlling interests		-	-
		109,171	(128,795)
Total profit/(loss) and comprehensive income for the financial year attributable to:			
Continuing operations		109,171	(128,795)
Discontinued operations		-	-
		109,171	(128,795)
Earnings per share for loss from continuing operation attributable to the shareholders of the Group		Cents	Cents
Basic and diluted profit/(loss) per share	23	0.40	(0.48)
Earnings per share for loss attributable to the shareholders of the Group		Cents	Cents
Basic and diluted profit/(loss) per share	23	0.40	(0.48)

The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes.

Oakridge International Limited
Consolidated Statement of Financial Position
As at 30 June 2026

		2026	2025
	Notes	\$	\$
Current assets			
Cash and cash equivalents	8	637,641	468,939
Other financial asset	9	61,948	61,948
Trade and other receivables	10	284,683	138,878
Prepayments	11	143,089	333,132
Inventory	12	795,724	380,757
Total current assets		1,923,085	1,383,654
Non-current assets			
Plant and equipment	13	144,085	64,873
Right of use assets	17	56,679	157,570
Total non-current assets		200,764	222,443
TOTAL ASSETS		2,123,849	1,606,097
Current liabilities			
Trade and other payables	14	420,773	290,764
Borrowings	15	32,548	32,548
Provisions	16	159,539	157,743
Lease liabilities	17	62,906	106,488
Unearned revenue	18	61,927	37,863
Total current liabilities		737,693	625,406
Non-current liabilities			
Provisions	16	24,743	15,540
Lease liabilities	17	-	62,905
Total non-current liabilities		24,743	78,445
TOTAL LIABILITIES		762,436	703,851
NET ASSETS		1,361,413	902,246
EQUITY			
Contributed equity	19	29,679,686	29,329,690
Reserves		32,088	32,088
Accumulated losses	20	(28,350,361)	(28,459,532)
TOTAL EQUITY		1,361,413	902,246

The above consolidated statement of financial position should be read in conjunction with the accompanying notes.

Oakridge International Limited
Consolidated Statement of Changes in Equity
For the year ended 30 June 2026

	Contributed equity \$	Share option reserve \$	Accumulated losses \$	Total \$
2025				
Balance at 1 July 2024	29,329,690	32,088	(28,330,737)	1,031,041
Loss for the year	-	-	(128,795)	(128,795)
Other comprehensive income	-	-	-	-
Total comprehensive income for the year	-	-	(128,795)	(128,795)
Transactions with owners in their capacity as owners:				
Ordinary shares issued, net of transaction costs	-	-	-	-
Balance at 30 June 2025	29,329,690	32,088	(28,459,532)	902,246
2026				
Balance at 1 July 2025	29,329,690	32,088	(28,459,532)	902,246
Profit / (loss) for the year	-	-	109,171	109,171
Other comprehensive income	-	-	-	-
Total comprehensive income for the year	-	-	109,171	109,171
Transactions with owners in their capacity as owners:				
Ordinary shares issued, net of transaction costs	349,996	-	-	349,996
Balance at 30 June 2026	29,679,686	32,088	(28,350,361)	1,361,413

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

Oakridge International Limited
Consolidated Statement of Cash Flows
For the year ended 30 June 2026

		2026	2025
	Notes	\$	\$
Cash flows from operating activities			
Receipts from customers		2,958,569	2,254,253
Interest received		2,061	266
Interest paid		(4,441)	(7,774)
Income Tax Paid		-	(3,537)
R&D incentives received		349,527	202,827
Payments to suppliers and employees		(3,178,688)	(2,804,492)
Net cash outflow from operating activities	22	127,028	(358,457)
Cash flows from investing activities			
Payments for plant and equipment		(101,838)	(37,224)
Interest received from rental holding security		-	2,152
Net cash inflow/(outflow) from investing activities		(101,838)	(35,072)
Cash flows from financing activities			
Ordinary shares issued, net of transaction costs	19	349,996	-
Proceeds from borrowings		250,000	-
Repayment of borrowings		(250,000)	-
Expenses converted to shares		(99,996)	-
Payment of lease liability	17	(106,488)	(99,107)
Net cash outflow from financing activities		143,512	(99,107)
Net increase/(decrease) in cash and cash equivalents		168,702	(492,636)
Cash and cash equivalents at the beginning of the year		468,939	961,575
Cash and cash equivalents at the end of the year	8	637,641	468,939

The above consolidated statement of cash flows should be read in conjunction with the accompanying notes.

1. Summary of material accounting policies

The principal accounting policies adopted in the preparation of these consolidated financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated. The financial statements relate to the Group consisting of Oakridge International Limited and its subsidiaries.

Oakridge International Limited is a publicly listed company limited by shares, incorporated and domiciled in Australia and listed on the Australian Securities Exchange (ASX: OAK). Its registered office is:

Suite 3 Level 3, 89 Pirie Street, Adelaide SA 5000.

Basis of preparation

This general purpose financial report has been prepared in accordance with Australian Accounting Standards (including Australian Accounting Interpretations) and the Corporations Act 2001. Oakridge International Limited is a for-profit entity for the purpose of preparing financial statements. All amounts are presented in Australian Dollars unless otherwise noted.

Compliance with IFRS

This financial report also complies with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board.

Historical cost convention

These financial statements have been prepared under the historical cost convention except for share-based payments which are measured in accordance with AASB 2 *Share-based Payments*.

Rounding of amounts

The Group is of a kind referred to in ASIC Corporations (Rounding in Financial/Directors' Reports) Instrument 2016/191, relating to the "rounding off" of amounts in the directors' report and financial report. The Group has rounded off amounts in the directors' report and financial report to the nearest dollar, in accordance with that instrument.

Critical accounting estimates and judgements

The preparation of financial statements in conformity with Australian Accounting Standards requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in Note 2.

New and amended standards adopted by the Group

The Group has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted by the consolidated entity for the annual reporting period ended 30 June 2026. The consolidated entity has not yet assessed the impact of these new or amended Accounting Standards and Interpretations.

1. Summary of material accounting policies (continued)

(a) Principles of consolidation

(i) Subsidiaries

The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Oakridge International Limited ("Company" or "Parent Entity") as at 30 June 2026 and the results of all subsidiaries for the year then ended. Oakridge International Limited and its subsidiaries together are referred to in this financial report as the Group or the consolidated entity.

Subsidiaries are all entities (including structured entities) over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date that control ceases.

Intercompany transactions, balances and unrealised gains on transactions between Group companies are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group.

Investments in subsidiaries are accounted for at cost in the individual financial statements of Oakridge International and are eliminated on consolidation for the purpose of preparing these financial statements.

(b) Foreign currency translation

(i) Functional and presentation currency

Items included in the financial statements of each of the Group's entities are measured using the currency of the primary economic environment in which the entity operated ("the functional currency"). The consolidated financial statements are presented in Australian dollars, which is the Group's functional and presentation currency.

(ii) Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss, except when they are deferred in equity as qualifying cash flow hedges and qualifying net investment hedges or are attributable to part of the net investment in a foreign operation.

(iii) Group companies

No subsidiaries in the Group have a functional currency which is different to the presentation currency of the Group.

(c) Revenue from contracts with customers

Revenue comprises revenue from the sale of goods, rendering of services, government grants and interest.

(i) Revenue recognised at a point in time

Revenue is recognised at a point in time (e.g. sale of goods) when the goods are received at a customer's specified location or control by the customer pursuant to a sales order, the risks of obsolescence and loss have passed to the customer, and the customer has either accepted the products in accordance with the sales contract, the acceptance provisions have lapsed, or the Group have objective evidence that all criteria for acceptance have been satisfied.

(ii) Revenue recognised over time

Service revenue is recognised on a straight line basis over the term of the contract as this best reflects the achievement of milestones, if specified in the contract, or costs incurred as a percentage of estimated total costs for each contract where the Group have an enforceable right to payment for performance completed. Where it is probable that a loss will arise from a fixed price service contract, the Group immediately recognise the excess of total costs over revenue as an expense.

(iii) R&D incentives

Government assistance R&D receipts are recognised in the statement of profit or loss and other comprehensive income when the Group has reasonable assurance that they will be received and that the Group will comply with the conditions attaching to them.

(iv) Interest revenue

Interest revenue is recognised as it accrues using the effective interest rate method.

1. Summary of material accounting policies (continued)

(d) Income tax

The income tax expense or revenue for the period is the tax payable on the current period's taxable income based on the national income tax rate adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses.

Deferred income tax is recognised for temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, the deferred income tax is not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the balance sheet date and are expected to apply when the related deferred income tax asset is realised, or the deferred income tax liability is settled.

Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses. Deferred tax liabilities and assets are not recognised for temporary differences between the carrying amounts and tax bases of investments in controlled entities where the parent entity is able to control the timing of the reversal of the temporary differences and it is probable that the differences will not reverse in the foreseeable future.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets and liabilities and when the deferred tax balances relate to the same taxation authority. Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Current and deferred tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, the tax is also recognised in other comprehensive income or directly in equity, respectively.

Tax consolidation legislation

Oakridge International and its wholly owned Australian controlled entities have implemented the tax consolidation legislation. As a consequence, these entities are taxed as a single entity and the deferred tax assets and liabilities of these entities are set off in the consolidated financial statements.

Current tax expense/income, deferred tax liabilities and deferred tax assets arising from temporary differences of the members of the tax-consolidated Group are recognised in the separate financial statements of the members of the tax consolidated Group, using the 'separate taxpayer within Group' approach by reference to the carrying amounts of assets and liabilities in the separate financial statements of each entity and the tax values applying under tax consolidation.

Any current tax liabilities or assets and deferred tax assets arising from unused tax losses of the subsidiaries are assumed by the head entity in the tax-consolidated Group and are recognised as amounts payable (receivable) to (from) other entities in the tax-consolidated Group in conjunction with any tax funding arrangement amounts referred to in the following section. Any difference between these amounts is recognised by the Group as an equity contribution or distribution.

The Group recognises deferred tax assets arising from unused tax losses of the tax-consolidated Group to the extent that it is probable that future taxable profits of the tax-consolidated Group will be available against which the asset can be utilised. Any subsequent period adjustment to deferred tax assets arising from unused tax losses, as a result of revised assessments of the probability of recoverability, is recognised by the head entity only.

Nature of tax funding arrangements and tax sharing arrangements

The head entity, in conjunction with other members of the tax-consolidated Group, has entered into a tax funding arrangement, which sets out the funding obligations of members of the tax-consolidated Group in respect of tax amounts.

The tax funding arrangements require payments to/from the head entity equal to the current tax liability (asset) assumed by the head entity and any tax-loss deferred tax asset assumed by the head entity, resulting in the head entity recognising an inter-entity receivable (payable) equal in amount to the tax liability (asset) assumed.

Contributions to fund the current tax liabilities are payable as per the tax funding arrangement and reflect the timing of the head entity's obligation to make payments for tax liabilities to the relevant tax authorities.

The head entity, in conjunction with other members of the tax-consolidated Group, has also entered into a tax sharing agreement. The tax sharing agreement provides for the determination of the allocation of income tax liabilities between the entities should the head entity default on its tax payment obligations. No amounts have been recognised in the financial statements.

1. Summary of material accounting policies (continued)

(e) Inventories

Inventories are measured at the lower of cost and net realisable value. Net realisable value represents the estimate selling price for inventories less all estimated costs of completion and costs necessary to make the sale.

(f) Plant and equipment

Property, plant and equipment is stated at historical cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. All other repairs and maintenance are charged to the income statement during the financial period in which they are incurred.

Depreciation of assets is calculated on the straight line and diminishing value methods to allocate their cost, net of their residual values, over their estimated useful lives. The depreciation rates used for each class of depreciable asset are:

Classification	Useful life	Depreciation basis
Plant and equipment	1-5 years	Diminishing value
Office equipment	1-20 years	Straight line
Computer equipment	1-4 years	Straight line
Software	2-2.5 years	Straight line
Motor vehicles	4 years	Diminishing value
Leasehold improvements	40 years	Straight line

The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at each balance sheet date.

An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

Gains and losses on disposals are determined by comparing proceeds with carrying amount. The difference between the sale proceeds and the carrying amount of an asset is recognised in the statement of profit or loss and other comprehensive income.

(g) Segment reporting

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the board of directors.

(h) Earnings per share

(i) Basic earnings per share

Basic earnings per share is calculated by dividing the profit attributable to owners of the company, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the year.

ii) Diluted earnings per share

Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of additional ordinary shares that would have been outstanding assuming the conversion of all dilutive potential ordinary shares.

(i) New accounting standards interpretations

The consolidated entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Standard Board ('AASB') that are mandatory for the current reporting period. The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the company.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

2. Critical accounting estimates, judgements and errors

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that may have a financial impact on the entity and that are believed to be reasonable under the circumstances. The critical estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

(a) Recoverability and classification of other receivable from K.S Orka

The Group has a receivable in relation to an additional payment from the sale of its interest in PT Sokoria Geothermal Indonesia. The payment of the receivable under the Payment Commitment Agreement between Oakridge International Limited and KS Orka Renewables Pte. Ltd. ('KS Orka') is triggered by KS Orka's Notice of Intent to Develop ('NOID') which is to be approved by PT PLN (Persero) under the Power Purchase Agreement ('PPA'). The Payment Multiple under the Payment Commitment Agreement is a factor of the Total Committed Capacity (as specified in the NOID) and the final negotiated Base Power Price per the PPA.

This receivable is carried at amortised cost less accumulated impairment. After taking into consideration the timing and final amount to be paid, management estimate the recoverable amount at 30 June 2026 to be \$Nil (2025: \$Nil). Any material change in the status of the project may result in a material change in the receivable to be recovered. This receivable has been classified as non-current at 30 June 2026 due to uncertainty in the timing of final settlement.

(b) Inventory

The Group assesses inventory for obsolescence each reporting date by evaluating whether the carrying value of inventory items exceeds its net realisable value. The net realisable value of the inventory is mainly determined based on assumptions of future demand within a specific time horizon. An allowance for obsolescence for the difference between the carrying value of an inventory items and its expected net realisable value.

(c) Deferred tax assets

The Group recognises deferred tax assets only to the extent that it is probable that future taxable profits, feasible tax planning strategies and deferred tax liabilities will be available against which the tax losses can be utilized. Estimation of the level of future taxable profits is therefore required in order to determine the appropriate carrying value of the deferred tax asset. Given the Group's past losses, plans to continue research and development in other indications and uncertainty of its ability to generate future taxable profit, the Group does not believe that it is more probable than not that the Group can realize its deferred tax assets and therefore, it has not recognised any amount in the consolidated statements of financial position. Additional information is included in Note 7.

(d) Receivables

The receivables at reporting date have been reviewed to determine whether there is any objective evidence that any of the receivables are impaired. For estimating the impairment of trade receivables, the Group applies the simplified approach permitted by AASB 9, which requires expected lifetime losses to be recognised from initial recognition of the receivables.

(e) Provisions

As described in the accounting policies, provisions are measured at management's best estimate of the expenditure required to settle the obligation at the end of the reporting period. These estimates are made taking into account a range of possible outcomes and will vary as further information is obtained.

Financial risk management

The Group's principal financial instruments include cash and cash equivalents, term deposits, trade and other receivables, trade and other payables, and borrowings. The Group's business activities can expose us to a variety of financial risks, including market risk (including foreign exchange risk, price risk and interest rate risk), credit risk and liquidity risk.

The Group's overall risk management program focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the Group's performance. We use sensitivity analysis to measure interest rate and foreign exchange risks, and aging for credit risk. The primary responsibility for risk management is carried out by the Group's executive director and CEO under policies approved by the Board of Directors. The executive directors and General Manager are responsible for the identification, evaluation and mitigation of financial risks.

It is the Group's policy that no trading in speculative financial instruments shall be undertaken. This does not prevent the Group from holding financial assets for strategic purposes.

Refer to Note 1 of these consolidated financial statements for further information on significant accounting policies applied, including the criteria for recognition of financial instruments, the basis of measurement, and the basis on which income and expenses are recognised.

(a) Financial instruments

The Group holds the following financial instruments:

	2026 \$	2025 \$
Financial assets		
Cash and cash equivalents	637,641	468,939
Other financial assets	61,948	61,948
Trade and other receivables	284,683	138,878
	984,272	669,765
Financial liabilities		
Trade and other payables	420,773	290,764
Borrowings	32,548	32,548
Lease liability	62,906	169,393
	516,227	492,705

All financial instruments are classified and measured at amortised cost.

The carrying amount of financial assets (net of any provision for impairment) and current financial liabilities approximate their fair value primarily because of their short maturities. The carrying amount of any non-current borrowings approximates fair value because the interest rate applicable to the borrowing approximates current market rates.

(b) Market risk

Foreign exchange risk

Foreign exchange risk arises when future commercial transactions and recognised assets and liabilities are denominated in a currency other than Australian dollars. From time to time the Group make sales to customers who require the currency of settlement to be a foreign currency. The Group has not entered into forward currency contracts to hedge these exposures due to the short time frame associated with the currency exposure and the Group's limited foreign currency exposure.

At 30 June 2026 and 2025 the Group's exposure to foreign currency risk was immaterial.

Price risk

The Group is not exposed to equity securities or commodity price risk.

3. Financial risk management (continued)

Interest rate risk

The Group's exposure to interest rate risk arise predominantly from cash and cash equivalents bearing variable interest rates. The Group's cash position fluctuates regularly, and ongoing liquidity needs mean most of the Group's funds are maintained in at-call accounts. The Group's term deposit and short-term borrowings are held in fixed interest rate accounts and are not subject to interest rate risks.

	30-Jun-26		30-Jun-25	
	Weighted average interest rate %	Balance \$	Weighted average interest rate %	Balance \$
Cash and cash equivalents	0.15%	637,641	0.15%	468,939

At balance sheet date, if the interest rates had changed, as illustrated in the table below, with all other variables remaining constant, after-tax profit and equity would have been affected as follows:

	After-tax profit higher / (lower)		Equity higher / (lower)	
	2026 \$	2025 \$	2026 \$	2025 \$
+1.00% (100 basis points)	6,376	4,689	6,376	4,689
-1.00% (100 basis points)	(6,376)	(4,689)	(6,376)	(4,689)

(c) Credit risk

Credit risk arises from financial assets of the Group, which comprises cash and cash equivalents, term deposits and trade and other receivables. The Group's exposure to credit risk arises from potential default of the counter party, with a maximum exposure equal to the carrying amount of these instruments. The Group does not hold any credit derivatives to offset the credit exposure.

Specific information as to the Group's credit risk exposures is as follows:

- Cash and cash equivalents and term deposits are maintained at the Commonwealth Bank of Australia
- Policies are in place to ensure that sales are made to customers with an appropriate credit history. The risk control procedures assess the credit quality of the customer, taking into account its financial position, past experience and other factors. The Group's customers generally do not have an independent credit rating. No collateral is obtained from customers.

The following table details the Group's trade and other receivables exposed to credit risk with aging analysis and expected credit loss provided for thereon. Amounts are considered as "past due" when the debt has not been settled within the terms and conditions agreed between the Group and the customer or counterparty to the transaction. Receivables that are past due are assessed for impairment by ascertaining solvency of the debtors and are provided for where there are specific circumstances indicating that the debt may not be fully repaid to the Group. The balance of receivables that remain within initial trade terms (as detailed in the table) are considered to be of high credit quality.

	Gross amount \$	Within trade terms current \$	31-60 days \$	61-90 days \$	90-365 days \$	365+ days \$	Credit loss allowance \$	Expected credit loss %
2026								
Trade receivables	284,684	284,684	-	-	-	-	-	0%
Other receivables	-	-	-	-	-	-	-	0%
	138,878	138,878	-	-	-	-	-	
2025								
Trade receivables	138,878	138,878	-	-	-	-	-	0%
Other receivables	-	-	-	-	-	-	-	0%
	138,878	138,878	-	-	-	-	-	

3. Financial risk management (continued)

(d) Liquidity risk

Prudent liquidity risk management implies maintaining sufficient cash and the availability of funding through an adequate amount of committed credit facilities in order to meet the Group's forecast requirements. The Group manages liquidity risk by continuously monitoring forecast and actual cash flows and matching the maturity profiles of financial assets and liabilities. Surplus funds are invested in term deposits. At reporting date, the Group did not have access to any undrawn borrowing facilities.

Maturity of financial liabilities

The table below categorises the Group's financial liabilities into relevant maturity Groups based on their contractual maturities, calculated as their undiscounted cash flows. All the financial liabilities are non-derivative.

	Less than 12 months	Between 1 and 5 years	Total contractual cash flows	Carrying amount
	\$	\$	\$	\$
<u>2026</u>				
<i>Non-interest bearing</i>				
Trade and other payables	420,773	-	420,773	420,773
Borrowings	-	32,548	32,548	32,548
	420,773	32,548	453,321	453,321
<i>Interest bearing</i>				
Lease liability	62,906	62,906	62,906	62,906
<u>2025</u>				
<i>Non-interest bearing</i>				
Trade and other payables	290,764	-	290,764	290,764
Borrowings	-	32,548	32,548	32,548
	290,764	32,548	323,312	323,312
<i>Interest bearing</i>				
Lease liability	106,488	62,905	169,393	169,393

Lease liabilities in the current period have an interest rate of 3.5% (2025: 3.5%) per annum. All other financial liabilities do not attract interest.

4. Operating segments

Identification of reportable segments

The Company has identified its operating segments based on the internal reports that are reviewed and used by the board of directors (chief operating decision makers) in assessing performance and determining the allocation of resources.

Reportable segments disclosed are based on aggregating operating segments where the segments are considered to have similar economic characteristics and meet the other aggregation criteria of AASB 8 *Operating Segments*.

Operating segment are Australian based unless otherwise stated.

Activity by segment

Healthcare technology

JCT Healthcare Pty Ltd ("JCT"), a wholly owned subsidiary of the Company, is a provider of innovative technology solutions for the healthcare sector. JCT develops and distributes its own range of nurse call hardware and software solutions for use across multiple healthcare sectors including hospitals, aged care, disability care and supported independent living.

Technology development

Technology focussed on the Internet of Things (IoT) technology.

Geothermal projects

Oakridge International held interests in three geothermal projects in Indonesia:

- Sokoria Geothermal Project, under a Joint Venture with PT Bakrie Power, for a 30 MW geothermal development on Flores Island, Indonesia, with Oakridge International holding a 45% interest in the project. On 16th January 2017 KS Orka completed acquisition of Sokoria Geothermal Project. Under the terms of the SPA Oakridge International received the nominal amount of US\$1. An additional payment of up to US\$947,368 will become payable within 30 days of KS Orka issuing notification of intent to develop project. This project has been fully impaired. In March 2022, Oakridge International received a notification of intent to develop a portion of the project which resulted in a payment from KS Orka of US\$157,939 or \$217,372. In April 2024, Oakridge International received a further payment of US\$94,763.80 or approximately \$144,810. Oakridge International may receive additional payments if KS Orka commits to further development.

Unallocated

Comprising corporate and overhead costs such as director's fees, listing and share registry fees, acquisitions and associated costs.

4. Operating segments (continued)

Segment performance

	Technology development \$	Healthcare technology \$	Geothermal projects \$	Unallocated \$	Total \$
Year ended 30 June 2026:					
Revenue from contracts with customers	-	3,094,420	-	-	3,094,420
R and D tax concession	-	262,362	-	87,165	349,527
Interest income	-	449	-	1,612	2,061
Total segment revenue	-	3,357,231	-	88,777	3,446,008
Cost of sales: inventories and other cost of sales	-	(1,401,241)	-	-	(1,401,241)
Employee and contracting expenses	-	(851,840)	-	(87,682)	(939,522)
Finance costs	-	(1,232)	-	(3,209)	(4,441)
Directors' fees	-	-	-	(247,992)	(247,992)
Consulting and advisory fees	(55,000)	-	-	(5,000)	(60,000)
Occupancy costs	-	(33,557)	-	(14,038)	(47,595)
Travel	-	(27,973)	-	(2,084)	(30,057)
Marketing and promotion costs	-	(38,228)	-	-	(38,228)
Professional and legal fees	-	(32,245)	-	(104,915)	(137,160)
Depreciation expense	-	(18,145)	-	(4,481)	(22,626)
Amortisation expense	-	(31,746)	-	(69,144)	(100,890)
Foreign currency (losses)/gains	-	(14,094)	-	(16)	(14,110)
Other expenses	-	(235,711)	-	(55,794)	(292,975)
Total segment expenses	(55,000)	(2,686,013)	-	(595,824)	(3,336,837)
Profit/(loss) before income tax for the year	(55,000)	671,218	-	(507,047)	109,171
Income tax benefit	-	-	-	-	-
Profit/(loss) for the year	(55,000)	671,218	-	(507,047)	109,171

4. Operating segments (continued)

	Technology development \$	Healthcare technology \$	Geothermal projects \$	Unallocated \$	Total \$
Year ended 30 June 2025:					
Revenue from contracts with customers	-	2,230,247	-	-	2,230,247
R and D tax concession	-	202,827	-	-	202,827
Interest income	-	-	-	266	266
Total segment revenue	-	2,433,074	-	266	2,433,340
Cost of sales: inventories and other cost of sales	-	(1,112,101)	-	-	(1,112,101)
Reversal of impairment loss on inventory	-	250,000	-	-	250,000
Employee and contracting expenses	(10,000)	(698,775)	-	(15,492)	(724,267)
Finance costs	-	(2,156)	-	(5,618)	(7,774)
Directors' fees	-	-	-	(247,992)	(247,992)
Consulting and advisory fees	-	-	-	(180,000)	(180,000)
Occupancy costs	-	(21,383)	-	(24,734)	(46,117)
Travel	-	(29,900)	-	(3,325)	(33,225)
Marketing and promotion costs	-	(48,181)	-	-	(48,181)
Professional and legal fees	-	(21,603)	-	(105,921)	(127,524)
Depreciation expense	-	(9,262)	-	(4,443)	(13,705)
Amortisation expense	-	(31,746)	-	(69,145)	(100,891)
Foreign currency (losses)/gains	-	(2,497)	-	111	(2,386)
Other expenses	-	(141,648)	-	(105,156)	(246,804)
Total segment expenses	(10,000)	(1,869,252)	-	(761,715)	(2,640,967)
Profit/(loss) before income tax for the year	(10,000)	563,822	-	(761,715)	(207,627)
Income tax benefit	-	78,832	-	-	78,832
Profit/(loss) for the year	(10,000)	642,654	-	(761,449)	(128,795)

Reconciliation of reportable segment revenues and profit or loss:

	2026 \$	2025 \$
Revenue		
Total revenue for reportable segments	3,446,008	2,433,340
Elimination of discontinued operations	-	-
Consolidated revenue from continuing operations	3,446,008	2,433,340
Profit or loss		
Total profit / (loss) for reportable segments	109,171	(207,627)
Elimination of discontinued operations	-	-
Consolidated profit / (loss) before income tax from continuing operations	109,171	(207,627)

4. Operating segments (continued)

Segment assets and liabilities

	Technology development \$	Healthcare technology \$	Geothermal projects \$	Unallocated \$	Eliminations \$	Total \$
As at 30 June 2026:						
Total assets	-	1,961,374	240	5,023,321	(4,861,086)	2,123,849
Total liabilities	-	(3,128,087)	(2,167,789)	(327,646)	4,861,086	(762,436)
As at 30 June 2025:						
Total assets	-	1,397,825	240	5,211,070	(5,003,038)	1,606,097
Total liabilities	-	(3,266,512)	(2,167,049)	(273,328)	5,003,038	(703,851)

5. Revenue and other income

	2026 \$	2025 \$
<i>Revenue from contracts with customers:¹</i>		
Revenue recognised at a point in time – sale of goods	2,908,722	2,004,339
Revenue recognised over time – projects and services	185,698	225,908
	<u>3,094,420</u>	<u>2,230,247</u>
<i>Other income:</i>		
Interest income	2,061	266
R and D tax concession	349,527	202,827
	<u>351,588</u>	<u>203,093</u>
	<u>3,446,008</u>	<u>2,433,340</u>

¹ All revenue from contracts with customers relates to the Healthcare Technology segment and is all derived within Australia.

6. Expenses

	2026 \$	2025 \$
Profit/(loss) before income tax includes the following specific expenses:		
Auditor's remuneration:		
Audit and other assurance services	54,000	47,567
Audit and review of financial reports	-	-
Tax and other services	-	-
Total auditor's remuneration	<u>54,000</u>	<u>47,567</u>
Superannuation expense	<u>101,652</u>	<u>75,897</u>

7. Income tax

	2026 \$	2025 \$
(a) Income tax expense		
Current tax	-	-
Deferred tax	(141,999)	(15,044)
Adjustments for deferred tax assets of prior periods	-	-
De-recognition of deferred tax asset	141,999	15,044
Income tax – prior years	-	(78,832)
	<u>-</u>	<u>(78,832)</u>

	2026 \$	2025 \$
(b) Reconciliation of income tax expense to prima facie income tax		
Loss before income tax	<u>109,171</u>	<u>(207,627)</u>
Tax at the Australian tax rate of 25% (2025: 25%)	27,293	(51,907)
Tax effect of amounts which are not deductible/(taxable) in calculating taxable income:		
Non-assessable income	(87,096)	(50,707)
Non-deductible expenses	1,582	1,090
Income tax – prior years	<u>200,220</u>	<u>195,400</u>
	141,999	93,876
Deferred tax asset not recognised	<u>(141,999)</u>	<u>(15,044)</u>
Income tax benefit	<u>-</u>	<u>78,832</u>

	2026 \$	2025 \$
(c) Unrecognised deferred tax assets		
Deferred tax assets have not been recognised in respect of the following items:		
Temporary differences at 25% (2025: 25%)	111,049	153,948
Tax losses at 25% (2025: 25%)	<u>10,422,397</u>	<u>10,366,055</u>
	<u>10,533,446</u>	<u>10,520,003</u>

Tax losses do not expire under current tax legislation. Deferred tax assets have not been recognised in respect of these losses because it is not probable that future taxable profit will be available against which the Group can utilise the benefits from the deferred tax assets.

8. Cash and cash equivalents

	2026	2025
	\$	\$
Cash on hand	-	-
Cash at bank	637,641	468,939
	<u>637,641</u>	<u>468,939</u>

9. Other financial asset

	2026	2025
	\$	\$
Term deposits	61,948	61,948
	<u>61,948</u>	<u>61,948</u>

The term deposit held at 30 June 2026 was used as security on a bank guarantee to secure the Company's obligations under the lease over the Company's corporate and subsidiary company offices.

10. Trade and other receivables

	2026	2025
	\$	\$
Current		
Trade receivables	284,683	138,878
Other receivables	-	-
	<u>284,683</u>	<u>138,878</u>
Non-current		
Other receivables – K.S. Orka	937,818	937,818
Impairment loss on other receivables	(937,818)	(937,818)
	<u>-</u>	<u>-</u>

11. Prepayments

	2026	2025
	\$	\$
Current		
Inventory	102,827	312,457
Expenses	40,262	20,675
	<u>143,089</u>	<u>333,132</u>

12. Inventory

	2026	2025
	\$	\$
Current		
Inventory	986,513	552,048
Provision for obsolescence	(190,789)	(190,789)
Inventory in transit	-	19,498
	<u>795,724</u>	<u>380,757</u>

13. Plant and equipment

	Plant and equipment \$	Software \$	Motor vehicle \$	Leasehold improvement \$	Total \$
Cost:					
At July 1, 2024	127,682	2,595	9,091	3,091	142,459
Additions	37,028	-	-	-	37,028
Disposal	-	-	-	-	-
At June 30, 2025	<u>164,710</u>	<u>2,595</u>	<u>9,091</u>	<u>3,091</u>	<u>179,487</u>
At July 1, 2025	164,710	2,595	9,091	3,091	179,487
Additions	103,837	-	-	-	103,837
Disposal	(1,999)	-	-	-	(1,999)
At June 30, 2026	<u>266,548</u>	<u>2,595</u>	<u>9,091</u>	<u>3,091</u>	<u>281,325</u>
Accumulated depreciation					
At July 1, 2024	86,328	2,595	9,091	3,091	101,105
Depreciation	13,705	-	-	-	13,705
Adjustment	(196)	-	-	-	(196)
Disposal	-	-	-	-	-
At June 30, 2025	<u>99,837</u>	<u>2,595</u>	<u>9,091</u>	<u>3,091</u>	<u>114,614</u>
At July 1, 2025	99,837	2,595	9,091	3,091	114,614
Depreciation	22,626	-	-	-	22,626
Disposal	-	-	-	-	-
At June 30, 2026	<u>122,463</u>	<u>2,595</u>	<u>9,091</u>	<u>3,091</u>	<u>137,240</u>
Carrying amount					
At June 30, 2025	<u>64,873</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>64,873</u>
At June 30, 2026	<u>144,085</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>144,085</u>

14. Trade and other payables

	2026	2025
	\$	\$
Current		
Trade payables	285,302	159,059
Accrued expenses	70,213	37,100
Other payables	65,258	94,605
	<u>420,773</u>	<u>290,764</u>

Trade payables are unsecured, non-interest bearing and are generally due 30 days from the date of recognition.

15. Borrowings

	2026	2025
	\$	\$
Current:		
Loan – Bio SA	<u>32,548</u>	<u>32,548</u>

On 1 December 2012, JCT Healthcare Pty Limited ("JCT"), a subsidiary of the Company, received a grant of \$230,000 under a Deed of Grant with Techin SA (formerly Bio Innovation SA) for the development of a web based messaging software licence. The development was completed on 30 June 2013. Pursuant to the Deed of Grant, for a period of 10 years ("Term of the Grant") the amount of the outstanding loan shall accrue annual indexation fees calculated at the Consumer Price Index on the outstanding loan amount. During this Term of the Grant, JCT is obligated to pay the loan from the royalties calculated on 7% of the income derived from the commercialization of the messaging software. The Deed of Grant terminated on 30 June 2023.

As at 30 June 2026, the current portion of the outstanding loan, inclusive of the accrual annual indexation fees, amounting to \$320,657 (2025: \$308,323) of which approximately \$32,548 (2025: \$32,548) is payable on the royalties outstanding and payable for the period from 1 July 2019 to 30 June 2026.

The web-based messaging software licence derived no royalty repayments for the year ended 30 June 2026 (2025: \$Nil) and it is not expected to derive any material royalty revenue and Loan repayments to the Group in the future. As a result, it is unlikely that JCT will need to repay the Loan amount of \$288,109, including any future annual indexation, as it will no longer derive any royalty income which is the basis of the Loan repayment. Accordingly, the Company has accounted \$32,548 for the amount of the royalties outstanding and payable as at 30 June 2026 (2025: \$32,548) in the Borrowings account on the balance sheet. The remaining balance of \$269,434 was accounted for in the Profit and Loss account as a reversal of borrowings in the 2023 financial year, and also disclosed in Note 24 as a contingent liability in the event of certain conditions set out in the Term of the Grant including JCT becoming bankrupted or move out of state of South Australia in the future.

16. Provisions

	2026 \$	2025 \$
Current		
Employee benefits	159,539	157,743
Provision for taxation	-	-
	<u>159,539</u>	<u>157,743</u>
Non-current		
Employee benefits	<u>24,743</u>	<u>15,540</u>

	Employee benefits \$	Taxation \$	Total \$
Opening balance at 1 July 2025	173,283	-	173,283
Increase/(decrease) in provision	10,999	-	10,999
Balance at 30 June 2026	<u>184,282</u>	<u>-</u>	<u>184,282</u>

17. Right of use assets and lease liabilities

	Property \$
Right of use assets	
Carrying amount at 1 July 2024	258,461
Additions	-
Amortisation	<u>(100,891)</u>
Carrying amount at 1 July 2025	157,570
Additions	-
Amortisation	<u>(100,891)</u>
Carrying amount at 30 June 2026	<u>56,679</u>

	2026 \$	2025 \$
Lease liabilities		
Current lease liabilities	62,906	106,488
Non-current lease liabilities	-	62,905
Total lease liabilities	<u>62,906</u>	<u>169,393</u>

Total payments for leases during the year comprise the following:

Principal payments	106,488	99,106
Interest expense	4,246	7,382
Payments made in relation to lease liabilities	<u>110,734</u>	<u>106,488</u>

Future payments of lease liabilities, including interest, are set out below:

Due within one year	63,667	110,735
Due between one year and five years	-	63,667
Due after five years	-	-
	<u>63,667</u>	<u>174,402</u>

In March 2023, the Company entered into an agreement to lease a corporate office for a term of four years from 13 March 2023 to 12 March 2027. The Company opened a term deposit which was used as security on a bank guarantee to secure the Company's obligations under the lease over the Company's corporate office.

In November 2023, JCT Healthcare Pty Ltd ("JCT"), a wholly owned subsidiary of the Company, entered into an agreement to lease an office for a term of three years from 15 November 2023 to 14 November 2026. JCT opened a term deposit which was used as security on a bank guarantee to secure the obligations under the lease over JCT's office.

18. Unearned Revenue

	2026	2025
	\$	\$
Opening Balance 01 July	37,863	43,584
less amounts recognised as revenue	(84,862)	(62,608)
plus cash received in advance	108,926	56,887
Closing Balance 30 June	<u>61,927</u>	<u>37,863</u>

19. Contributed equity,

	2026	2025
	No.	No.
<u>Ordinary shares – fully paid</u>	<u>31,997,851</u>	<u>26,997,908</u>
(a) <u>Movements in equity</u>	No.	No.
Balance at 1 July	26,997,908	26,997,908
Employee Share Issuance	-	-
Cash Share Issuance (note c below)	4,999,943	-
Balance at 30 June	<u>31,997,851</u>	<u>26,997,908</u>

(b) Employee share option scheme

The Group did not issue any share options during the financial year.

In prior financial years, the Company issued the following stock options to qualified employees:

On 14 November 2023, the Company issued 306,480 unlisted options to its employees which are exercisable at \$0.10 per option and expire on 13 November 2026. As at the balance date and the date of this report, none of the 306,480 unlisted options have been exercised.

On 20 December 2023, the Company issued 599,970 unlisted options exercisable at \$0.10 expiring 19 December 2026 to an entity associated with Mr. Unerkov, a director of the Company. As at the balance date and the date of this report, none of the 599,970 unlisted options have been exercised.

(c) Options issued during the financial year

The Group did not issue any share options during the financial year.

In prior financial years, at a members meeting, the shareholders approved the issuance of 9,398,496 shares at a share price of \$0.0532 and 7,142,857 unlisted options with an exercise price of \$0.07 and an expiry date of 30 June 2026 to Montague Capital Pty Ltd.

On 30 June 2026, 4,999,943 options were exercised by Montague Capital Pty Ltd and the remaining amount of 2,142,914 options expired without exercise or conversion.

As at the date of this report, there are no outstanding unlisted options other than the employee share options disclosed in Note 19. (b).

(d) Capital management

With regard to managing capital (equity), the director's objectives are to ensure the Group continues as a going concern as well as to maintain optimal returns to shareholders and benefits for other stakeholders. The board adjusts the capital structure as necessary to take advantage of favourable costs of capital or high returns on assets. As the market is constantly changing, the board may change the amount of dividends to be paid to shareholders, return capital to shareholders, issue new shares or reduce debt that may be incurred to acquire assets.

No dividends were paid during the year (2025: \$nil).

20. Accumulated losses

	2026	2025
	\$	\$
Accumulated losses	(28,350,361)	(28,459,532)
The movement in the accumulated losses comprises:		
Balance at beginning of financial year	(28,459,532)	(27,330,737)
Profit/(loss) for the financial year	109,171	(128,795)
Balance at end of financial year	(28,350,361)	(28,459,532)

21. Key management personnel and related party disclosures

	2026	2025
	\$	\$
(a) Key management personnel compensation		
Short-term employee benefits	247,992	247,992
Post employment benefits	-	-
Long term benefits	-	-
Share based payments	-	-
	247,992	247,992

(b) Other transactions with key management personnel

There were no other transactions with key management personnel during the financial year.

(c) Transactions with other related parties

During the financial year ended 30 June 2026, a related party of Mr. Unerkov , was paid a fee in addition to statutory superannuation contributions, to perform part-time administrative services for a wholly-owned subsidiary of the Company. The fee for the full year was \$4,166.67 per month.

22. Cash flow information	2026	2025
	\$	\$
<i>Reconciliation of loss after income tax to net cash outflow from operating activities:</i>		
Profit/(loss) for the year	109,171	(128,795)
<u>Non-cash items in profit or loss:</u>		
Depreciation expense	22,626	13,706
Amortisation expense	100,891	100,891
Expenses converted to shares	99,996	-
Reversal of impairment loss on inventory	-	(250,000)
Reversal of income tax provision	-	(78,832)
<u><i>Change in operating assets and liabilities:</i></u>		
(Increase)/ decrease in trade or other receivables	(145,805)	32,113
Decrease/ (increase) in inventory	(414,966)	174,930
Decrease/ (increase) in other current assets	190,043	(327,510)
(Decrease)/ increase in trade and other payables	130,009	97,691
Increase in provisions	10,999	13,070
(Decrease)/increase in unearned revenue	24,064	(5,721)
Net cash outflow from operating activities	<u>127,028</u>	<u>(358,457)</u>

23. Earnings per share

	2026	2025
	Cents	Cents
(a) Basic and diluted earnings per share		
Profit/(loss) from continuing operations attributable to the ordinary equity holders of the Group	0.40	(0.48)
Profit/(loss) from discontinued operations attributable to the ordinary equity holders of the Group	-	-
Profit/(loss attributable to the ordinary equity holders of the Group	<u>0.40</u>	<u>(0.48)</u>

(b) Weighted average number of ordinary shares used as the denominator

		2026	2025
	Note	No.	No.
Number used in calculating basic and diluted earnings per share at 1 July		26,997,908	26,997,908
Effect of shares issued by private placement	19	4,999,943	-
Effect of shares issued	19	-	-
Number used in calculating basic and diluted earnings per share at 30 June		<u>31,997,851</u>	<u>26,997,908</u>

(c) Information concerning earnings per share

There were a total of 906,450 unlisted options outstanding at the end of 2026 financial year.

24. Parent entity disclosures

(a) Summary financial information

The individual financial statements for the parent entity, Oakridge International Limited, show the following aggregations.

	2026	2025
	\$	\$
Results		
Loss for the financial year	(560,452)	(770,486)
Total comprehensive loss for the financial year	(560,452)	(770,486)
Financial position		
Current assets	131,450	73,075
Non-current assets	8,012,568	8,227,934
	8,144,018	8,301,009
Current liabilities	321,801	216,926
Non-current liabilities	-	51,410
	321,801	268,336
Net assets	7,822,217	8,032,673
Contributed equity	75,580,442	75,230,446
Reserves	32,088	32,088
Accumulated losses	(67,790,313)	(67,229,861)
	7,822,217	8,032,673

(b) Guarantees entered into by the parent entity

Oakridge International Limited has not guaranteed the debts of any of its subsidiaries in the Group.

(c) Contingent liabilities of the parent entity

On 31 December 2019, Oakridge International Limited entered into a Share Placement Agreement ("SPA") issuing 250 million ordinary shares in the Group at \$0.001 per ordinary share, on a pre consolidated basis, for total proceeds of \$250,000. At the time of this transaction, Mr Con Unerkov was appointed to the Board of the parent company. Pursuant to the SPA, the parent company made certain representations in respect to liabilities in the Group to Teko International Limited, the purchaser. However, in the process of preparing the Group's accounts for the year ended 30 June 2020, the Group became aware that some of the representations made by the Group were not accurate.

The Parent is currently seeking legal advice to determine the extent of its legal liabilities in respect of a potential breach of the SPA. At the date of this report, the Group has not been able to quantify the liability, if any, in respect to these breaches.

(d) Contractual commitments for capital expenditure

The parent entity did not have any contractual commitments for capital expenditure as at 30 June 2026.

(e) Corporate office lease bank guarantee

In March 2023, the Company entered into an agreement to lease a corporate office for a term of four years from 13 March 2023 to 12 March 2027. The Company opened a term deposit which was used as security on a bank guarantee to secure the Company's obligations under the lease over the Company's corporate office.

25. Contingent liabilities

Other than the contingent liabilities below, the Group had no other contingent liabilities as at 30 June 2026.

On 1 December 2012, JCT Healthcare Pty Ltd ("JCT"), a subsidiary of the Company, received a grant of \$230,000 under a Deed of Grant with Techin SA (formerly Bio Innovation SA) for the development of a web based messaging software licence. The development was completed on 30 June 2013. Pursuant to the Deed of Grant, for a period of 10 years ("Term of the Grant") the amount of the outstanding loan shall accrue annual indexation fees calculated at the Consumer Price Index on the outstanding loan amount. During this Term of the Grant, JCT is obligated to pay the loan from the royalties calculated on 7% of the income derived from the commercialization of the messaging software. The Deed of Grant terminated on 30 June 2023.

As at 30 June 2026, the current portion of the outstanding loan, inclusive of the accrual annual indexation fees, amounting to \$320,657 (2025: \$308,323) of which approximately \$32,548 (2025: \$32,548) is payable on the royalties outstanding and payable for the period from 1 July 2019 to 30 June 2026.

The web-based messaging software licence derived no royalty repayments for the year ended 30 June 2026 (2025: \$Nil) and it is not expected to derive any material royalty revenue and Loan repayments to the Group in the future. As a result, it is unlikely that JCT will need to repay the Loan amount of \$288,109, including any future annual indexation, as it will no longer derive any royalty income which is the basis of the Loan repayment. Accordingly, the Company has accounted \$32,548 for the amount of the royalties outstanding and payable as at 30 June 2026 (2025: \$32,548) in the Borrowings account on the balance sheet (Note 15). The remaining balance of \$269,434 was accounted for in the Profit and Loss account as a reversal of borrowings in the 2023 financial year, and also disclosed as a contingent liability in the event of certain conditions set out in the Term of the Grant including JCT becoming bankrupted or move out of state of South Australia in the future.

In March 2023, the Company entered into an agreement to lease a corporate office for a term of four years from 13 March 2023 to 12 March 2027. The Company opened a term deposit which was used as security on a bank guarantee to secure the Company's obligations under the lease over the Company's corporate office.

In November 2023, JCT Healthcare Pty Ltd ("JCT"), a wholly owned subsidiary of the Company, entered into an agreement to lease an office for a term of three years from 15 November 2023 to 14 November 2026. JCT opened a term deposit which was used as security on a bank guarantee to secure the obligations under the lease over JCT's office.

26. Commitments

	2026	2025
	\$	\$
Operating leases		
Due within one year	62,905	106,488
Due between one year and five years	-	62,905
Due after five years	-	-
	62,905	169,393

27. Controlled entities

The consolidated financial statements incorporate the assets, liabilities and results of the following subsidiaries in accordance with the accounting policy described in Note 1(a).

Name of entity	Country of incorporation	Class of shares	Equity holding	
			2026	2025
			%	%
Oakridge Asia Holdings Pty Ltd	Australia	Ordinary	100	100
Oakridge Healthcare Pty Ltd	Australia	Ordinary	100	100
Osiris Energy Pty Ltd ⁽¹⁾	Australia	Ordinary	100	100
JCT Healthcare Pty Ltd	Australia	Ordinary	100	100

Interests in joint arrangements

The Group has the following significant interests in joint arrangements.

(a) Joint arrangements

Sokoria Geothermal Project, under a Joint Venture with PT Bakrie Power, for a 30 MW geothermal development on Flores Island, Indonesia, with Oakridge holding a 45% interest in the project. On 16 January 2017 KS Orka completed acquisition of Sokoria Geothermal Project. Under the terms of the SPA Oakridge received the nominal amount of US\$1. An additional payment of up to US\$947,368 will become payable within 30 days of KS Orka issuing notification of intent to develop project. This project has been fully impaired. In March 2022, Oakridge received a notification of intent to develop a portion of the project which resulted in a payment from KS Orka of US\$157,939 or \$217,372. In April 2024, Oakridge received a further payment of US\$94,763.80 or approximately \$144,810. Oakridge may receive additional payments if KS Orka commits to further development.

28. Subsequent events

There were no other significant events after the financial year end.

OAKRIDGE INTERNATIONAL LIMITED
CONSOLIDATED ENTITY DISCLOSURE STATEMENT

Name of entity	Country of incorporation	Type of entity	Percentage owned (%)	Trustee of a Trust or partner in a partnership in a joint venture	Australian or Foreign?	If foreign list each jurisdiction of tax residency
			2026			
Oakridge Asia Holdings Pty Ltd	Australia	Proprietary Company	100	N/A	Australian	N/A
Oakridge Healthcare Pty Ltd	Australia	Proprietary Company	100	N/A	Australian	N/A
Osiris Energy Pty Ltd	Australia	Proprietary Company	100	N/A	Australian	N/A
JCT Healthcare Pty Ltd	Australia	Proprietary Company	100	N/A	Australian	N/A

OAKRIDGE INTERNATIONAL LIMITED

DIRECTORS' DECLARATION

In the directors' opinion:

- (a) the attached financial statements and notes are in accordance with the *Corporations Act 2001*, including:
 - (i) complying with Australian Accounting Standards and the Corporations Regulations 2001; and
 - (ii) giving a true and fair view of the Group's financial position as at 30 June 2026 and of its performance, as represented by the results of its operations and its cash flows, for the financial year ended on that date;
- (b) the financial report also complies with International Financial Reporting Standards as disclosed in Note 1(a);
- (c) there are reasonable grounds to believe that the Group will be able to pay its debts as and when they become due and payable;
- (d) the directors have been given the declarations required by section 295A of the *Corporations Act 2001*; and
- (e) the information detailed in the consolidated entity disclosure statement is true and correct.

This declaration is made in accordance with a resolution of directors.



Con Unerkov
Chairman

Adelaide, South Australia
24 August 2026

Additional information required by the Australian Securities Exchange Ltd Listing Rules and not disclosed elsewhere in this report is as follows. This information is current as at 4 August 2026.

Twenty largest shareholders

Rank	Name of holder	No. of ordinary shares held	Issued capital %
1	MONTAGUE CAPITAL PTY LTD	16,898,439	52.81
2	TEKO INTERNATIONAL LIMITED	3,125,000	9.77
3	ALITON PTY LTD <BELL FAMILY SUPER FUND A/C>	1,674,309	5.23
4	HEURESYS LABS LLC	1,000,000	3.13
5	MR GABRIEL GOVINDA	719,944	2.25
6	JK GROUP AUSTRALIA PTY LTD <JK FAMILY A/C>	701,441	2.19
7	AEROBOTICS PTY LTD	370,000	1.16
8	BNP PARIBAS NOMINEES PTY LTD <CLEARSTREAM>	347,921	1.09
9	ALANTICX TECHNOLOGIES PTY LTD <ALANTICX A/C>	222,084	0.69
10	ALITON PTY LTD	220,013	0.69
11	MR SHUHUA DENG	220,000	0.69
12	MR JONATHAN BERNARD SINGER	203,890	0.64
13	MR MOHAMMED AKBAR ASEM	185,184	0.58
14	BNP PARIBAS NOMINEES PTY LTD <UOBKH R'MIERS>	179,472	0.56
15	SHARESIES AUSTRALIA NOMINEE PTY LIMITED	177,294	0.55
16	MISS NICOLE GEK LEN TAN	169,291	0.53
17	MR RAMIN VAHDANI	159,064	0.50
18	MR BOBBY VINCENT LI	146,062	0.46
19	TOWNS CORPORATION PTY LTD <PAE FAMILY A/C>	130,138	0.41
20	BNP PARIBAS NOMINEES PTY LTD <IB AU NOMS RETAILCLIENT>	126,877	0.40
	Total	26,976,423	84.31
	Total issued capital	31,997,851	100.00

Substantial shareholders

Substantial shareholders as advised to the Group are set out below:

Name of holder	No. of ordinary shares held	Issued capital %
MONTAGUE CAPITAL PTY LTD	16,898,439	52.81
TEKO INTERNATIONAL LIMITED	3,125,000	9.77
ALITON PTY LTD <BELL FAMILY SUPER FUND A/C>	1,674,309	5.23

Distribution of member holdings

Holding ranges	Holders	Total units	%issued share capital
1 - 1,000	193	54,152	0.17
1,001 - 5,000	229	706,787	2.21
5,001 - 10,000	93	684,347	2.14
10,001 - 100,000	114	3,331,642	10.41
100,001 - 9,999,999,999	22	27,220,923	85.07
Totals	651	31,997,851	100.00%

The number of security investors holding less than a marketable parcel of securities is 461 with a combined total of 987,394 securities.

Voting rights

All shares carry one vote per share without restriction.

VICTORIA

Level 44, 600 Bourke Street
Melbourne VIC 3000
T +61 3 9608 0100

Level 3, 237 Ryrie Street
Geelong VIC 3220
T +61 3 5215 6800

TASMANIA

Level 3, 63-65 Cameron Street
Launceston TAS 7250
T +61 3 6334 0500

victoria@moore-australia.com.au
www.moore-australia.com.au

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF OAKRIDGE INTERNATIONAL LIMITED AND CONTROLLED ENTITIES

Report on the Audit of the Financial Report

Opinion

We have audited the financial report of Oakridge International Limited (the Company), and its subsidiaries (the Group) which comprises the consolidated statement of financial position as at 30 June 2026, the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the financial statements, including a summary of material accounting policy information, the consolidated entity disclosure statement and the directors' declaration.

In our opinion, the accompanying financial report of the Group is in accordance with the *Corporations Act 2001*, including:

- i. giving a true and fair view of the Group's consolidated financial position as at 30 June 2026 and of its consolidated financial performance for the year then ended; and
- ii. complying with Australian Accounting Standards and the *Corporations Regulations 2001*.

Basis for Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Company in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report of the current period. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key Audit Matter
How the matter was addressed in our audit
KEY AUDIT MATTER – INVENTORY VALUATION

Refer to Note 12: Inventory

As of 30 June 2026, the Group reported inventory on hand totalling \$795,723, which includes a provision for inventory obsolescence amounting to \$190,789 (included as a deduction).

The valuation of inventory is considered a key audit matter due to the significant judgment and estimation involved in determining the appropriate provision for obsolete stock.

Our procedures included, amongst others:

- obtaining and evaluating management's assessment of inventory obsolescence.
- evaluating the reasonableness and accuracy of key assumptions,
- performing net realisable value testing on a sample of inventory on hand at year end; and
- assessing the adequacy of the disclosures in the financial report.

Other Information

The directors are responsible for the other information. The other information comprises the information included in the Company's annual report for the year ended 30 June 2026, but does not include the financial report and our auditor's report thereon.

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed on the other information that we obtained prior to the date of this auditor's report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Directors for the Financial Report

The directors of the Company are responsible for the preparation of:

- a) the financial report (other than the consolidated entity disclosure statement) that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001*; and
- b) the consolidated entity disclosure statement that is true and correct in accordance with the *Corporations Act 2001*, and for such internal control as the directors determine is necessary to enable the preparation of:
 - i. the financial report (other than the consolidated entity disclosure statement) that gives a true and fair view and is free from material misstatement, whether due to fraud or error; and
 - ii. the consolidated entity disclosure statement that is true and correct and is free of misstatement, whether due to fraud or error.

Auditor's Responsibilities for the Audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located on the Auditing and Assurance Standards Board website at:

https://www.auasb.gov.au/admin/file/content102/c3/ar1_2024.pdf (Group Audit). This description forms part of our auditor's report.

Report on the Remuneration Report

Opinion on the Remuneration Report

We have audited the Remuneration Report included in pages 7 to 11 of the directors' report for the year ended 30 June 2026.

In our opinion, the Remuneration Report of Oakridge International Limited, for the year ended 30 June 2026 complies with section 300A of the *Corporations Act 2001*.

Responsibilities

The directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.



ANDREW JOHNSON
Partner – Audit and Assurance
[Moore Australia Audit \(VIC\)](#)
Melbourne, Victoria
24 August 2026

Moore Australia
Moore Australia Audit (VIC)
ABN 16 847 721 257
Chartered Accountants